Journal of Public Health Policy and Planning

Reach Us +44-7897-074717

Mini Review - Journal of Public Health Policy and Planning (2024) Volume 8, Issue 1

Beyond vaccines: exploring promising therapeutic approaches in the fight against coronavirus

Lennard Lee *

Department of Oncology, University of Oxford, UK

*Corresponding Author:
Lennard Lee
Department of Oncology, University of Oxford, UK
E-mail: len.lee@oncology.ox.ac.uk

Received: : 26-Dec-2023, Manuscript No. . AAPHPP-24-129705; Editor assigned: 26-Dec-2023, PreQC No. AAPHPP-24-129705 (PQ); Reviewed:11- Jan-2024, QC No. AAPHPP-24-129705; Revised:17- Jan -2024, Manuscript No. AAPHPP-24-129705 (R); Published:22- Jan -2024, DOI:10.35841/aara- aaphpp-8.1.211

Citation: Beyond vaccines: exploring promising therapeutic approaches in the fight against coronavirus. J Public Health Policy Plan. 2023;8(1):211

Visit for more related articles at Journal of Public Health Policy and Planning

Abstract

     

Introduction

The COVID-19 pandemic has spurred an unprecedented global effort to develop vaccines, resulting in remarkable achievements in record time. Vaccination campaigns have undoubtedly played a pivotal role in curbing the spread of the virus and reducing the severity of illness. However, as the virus continues to evolve and new variants emerge, the quest for effective therapeutic approaches remains crucial. Beyond vaccines, researchers are exploring a diverse array of therapeutic strategies to combat COVID-19 and its variants [1].

Monoclonal antibodies (mAbs) have emerged as a promising therapeutic option against COVID-19. These laboratory-produced molecules mimic the immune system's ability to fight off harmful pathogens. Several mAbs, including bamlanivimab and casirivimab/imdevimab, have received emergency use authorization for treating mild to moderate COVID-19 cases, particularly in high-risk individuals. These antibodies bind to specific regions of the virus, preventing it from entering and infecting human cells. Ongoing research focuses on optimizing mAb cocktails to enhance efficacy and combat emerging variants [2].

Antiviral medications have long been instrumental in managing viral infections, and COVID-19 is no exception. Remdesivir, an antiviral drug initially developed for Ebola, has demonstrated efficacy in reducing the recovery time for hospitalized COVID-19 patients [3].

Additionally, molnupiravir, an oral antiviral medication, has shown promise in clinical trials for treating mild to moderate COVID-19 cases. These drugs work by targeting various stages of the viral replication cycle, inhibiting the virus's ability to spread within the body [4].

Convalescent plasma therapy involves using blood plasma from recovered COVID-19 patients, which contains antibodies against the virus, to treat individuals with active infections. While initial studies suggested potential benefits, the efficacy of this therapy remains under scrutiny due to inconsistent results from clinical trials. Challenges such as variable antibody levels in donor plasma and the emergence of new variants have prompted researchers to explore alternative approaches, including the development of hyperimmune globulin formulations with standardized antibody levels [5].

Severe cases of COVID-19 often involve dysregulated immune responses, leading to inflammatory damage in the lungs and other organs. Immunomodulatory therapies aim to regulate the immune system's response to prevent excessive inflammation and tissue damage [6].

Severe cases of COVID-19 often involve dysregulated immune responses, leading to inflammatory damage in the lungs and other organs. Immunomodulatory therapies aim to regulate the immune system's response to prevent excessive inflammation and tissue damage. Corticosteroids, such as dexamethasone, have demonstrated efficacy in reducing mortality rates among critically ill COVID-19 patients by dampening inflammatory responses. Other immunomodulatory agents, such as tocilizumab and baricitinib, are being investigated for their potential to mitigate severe COVID-19 symptoms by targeting specific immune pathways [7].

Host-directed therapies target host factors essential for viral replication and pathogenesis, offering a broad-spectrum approach against various viruses, including SARS-CoV-2. Drugs like ivermectin, originally developed as an antiparasitic agent, have garnered attention for their potential antiviral properties against COVID-19. However, the efficacy of such therapies remains contentious, requiring further rigorous clinical evaluation. Additionally, repurposing existing drugs with known safety profiles for COVID-19 treatment offers a cost-effective strategy to expedite therapeutic development [8].

Severe cases of COVID-19 often involve dysregulated immune responses, leading to inflammatory damage in the lungs and other organs. Immunomodulatory therapies aim to regulate the immune system's response to prevent excessive inflammation and tissue damage. Corticosteroids, such as dexamethasone, have demonstrated efficacy in reducing mortality rates among critically ill COVID-19 patients by dampening inflammatory responses. Other immunomodulatory agents, such as tocilizumab and baricitinib, are being investigated for their potential to mitigate severe COVID-19 symptoms by targeting specific immune pathways [9].

Moreover, the emergence of new variants underscores the need for adaptable therapeutic strategies capable of targeting evolving viral strains. Collaborative efforts between researchers, clinicians, and pharmaceutical companies will be essential in advancing novel therapeutics and navigating the complex challenges posed by COVID-19 [10].

conclusion

While vaccines have played a pivotal role in combating the COVID-19 pandemic, the search for effective therapeutic approaches remains imperative. From monoclonal antibodies to host-directed therapies, a diverse array of treatment options holds promise in mitigating the impact of COVID-19 and its variants. Continued research and collaboration are essential to optimize existing therapies, develop novel interventions, and ultimately enhance our arsenal against this global health crisis. As the world grapples with the on going challenges of COVID-19, the pursuit of innovative therapeutics offers hope for a brighter future. .

References

  1. Mattingly C. The concept of therapeutic ‘emplotment’. Social science & medicine. 1994 ;38(6):811-22.

    2.                Indexed at, Google Scholar, Cross Ref

  2. Draelos ZD. Therapeutic moisturizers. Dermatologic clinics. 2000;18(4):597-607.

    3.                Indexed at, Google Scholar, Cross Ref

  3. Kralisch S, Klein J, Bluher M,et al. Therapeutic perspectives of adipocytokines. Expert opinion on pharmacotherapy. 2005;6(6):863-72.

    Indexed at, Google Scholar, Cross Ref

  4. Zheng CJ, Han LY, Yap CW,et al. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacological reviews. 2006;58(2):259-79.

    5.                 Indexed at, Google Scholar, Cross Ref

  5. Main TF. The hospital as a therapeutic institution. Bulletin of the Menninger Clinic. 1946;10(3):66.

    6. Indexed at, Google Scholar, Cross Ref

  6. Caplan AI. Why are MSCs therapeutic? New data: new insight. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2009;217(2):318-24.

    7. Indexed at, Google Scholar, Cross Ref

  7. Winum JY, Scozzafava A, Montero JL, et al. Sulfamates and their therapeutic potential. Medicinal research reviews. 2005;25(2):186-228.

    8.                 Indexed at, Google Scholar, Cross Ref

  8. Neki JS. Gur?-Chel? relationship: The possibility of a therapeutic paradigm. American Journal of Orthopsychiatry. 1973;43(5):755.

    9.                 Indexed at, Google Scholar, Cross Ref

  9. 9.Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochemistry and Photobiology. 1995;61(6):529-39.

     

                    Indexed at, Google Scholar, Cross Ref

  10. Mattingly C. The concept of therapeutic ‘emplotment’. Social science & medicine. 1994 ;38(6):811-22.

    11.                 Indexed at, Google Scholar, Cross Ref

     

 

Get the App